260 related articles for article (PubMed ID: 8313401)
1. Reversible monoamine oxidase-A inhibitors in panic disorder.
Bakish D; Saxena BM; Bowen R; D'Souza J
Clin Neuropharmacol; 1993; 16 Suppl 2():S77-82. PubMed ID: 8313401
[TBL] [Abstract][Full Text] [Related]
2. Brofaromine in panic disorder: a pilot study with a new reversible inhibitor of monoamine oxidase-A.
Garcia-Borreguero D; Lauer CJ; Ozdaglar A; Wiedemann K; Holsboer F; Krieg JC
Pharmacopsychiatry; 1992 Nov; 25(6):261-4. PubMed ID: 1494591
[TBL] [Abstract][Full Text] [Related]
3. MAO inhibitors in panic disorder: clinical effects of treatment with brofaromine. A double blind placebo controlled study.
van Vliet IM; Westenberg HG; Den Boer JA
Psychopharmacology (Berl); 1993; 112(4):483-9. PubMed ID: 7871061
[TBL] [Abstract][Full Text] [Related]
4. The use of the reversible monoamine oxidase-A inhibitor brofaromine in social phobia complicated by panic disorder with or without agoraphobia.
Bakish D
J Clin Psychopharmacol; 1994 Feb; 14(1):74-5. PubMed ID: 8151007
[No Abstract] [Full Text] [Related]
5. Reversible monoamine oxidase-A inhibitors in resistant major depression.
Nolen WA; Hoencamp E; Bouvy PF; Haffmans PM
Clin Neuropharmacol; 1993; 16 Suppl 2():S69-76. PubMed ID: 8313400
[TBL] [Abstract][Full Text] [Related]
6. Reversible monoamine-A inhibitors in panic disorder.
Bakish D
Clin Neuropharmacol; 1992; 15 Suppl 1 Pt A():432A-433A. PubMed ID: 1498904
[No Abstract] [Full Text] [Related]
7. The efficacy of reversible monoamine oxidase inhibitors in depressive illness.
Roth M; Guelfi JD
Can J Psychiatry; 1992 Sep; 37 Suppl 1():18-24. PubMed ID: 1394027
[TBL] [Abstract][Full Text] [Related]
8. Tricyclic antidepressants and monoamine oxidase inhibitors in the treatment of agoraphobia.
Pohl R; Berchou R; Rainey JM
J Clin Psychopharmacol; 1982 Dec; 2(6):399-407. PubMed ID: 7174863
[TBL] [Abstract][Full Text] [Related]
9. Superiority of clomipramine over imipramine in the treatment of panic disorder: a placebo-controlled trial.
Modigh K; Westberg P; Eriksson E
J Clin Psychopharmacol; 1992 Aug; 12(4):251-61. PubMed ID: 1527228
[TBL] [Abstract][Full Text] [Related]
10. The use of the Panic and Agoraphobia Scale (P & A) in a controlled clinical trial.
Bandelow B; Broocks A; Pekrun G; George A; Meyer T; Pralle L; Bartmann U; Hillmer-Vogel U; Rüther E
Pharmacopsychiatry; 2000 Sep; 33(5):174-81. PubMed ID: 11071019
[TBL] [Abstract][Full Text] [Related]
11. Brofaromine in non-endogenous major depressed inpatients--results of a preliminary dose-finding trial versus tranylcypromine.
Volz HP; Heimann H; Bellaire J; Laux G; Möller HJ
Pharmacopsychiatry; 1994 Jul; 27(4):152-8. PubMed ID: 7972347
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic and side-effect profile of a selective and reversible MAO-A inhibitor, brofaromine. Results of dose-finding trials in depressed patients.
Schiwy W; Heath WR; Delini-Stula A
J Neural Transm Suppl; 1989; 28():33-44. PubMed ID: 2677240
[TBL] [Abstract][Full Text] [Related]
13. Studies of selective and reversible monoamine oxidase inhibitors.
Mann JJ; Aarons SF; Frances AJ; Brown RD
J Clin Psychiatry; 1984 Jul; 45(7 Pt 2):62-6. PubMed ID: 6429130
[TBL] [Abstract][Full Text] [Related]
14. Monoamine oxidase, monoamine oxidase inhibitors, and panic disorder.
Norman TR; Burrows GD
J Neural Transm Suppl; 1989; 28():53-63. PubMed ID: 2677243
[TBL] [Abstract][Full Text] [Related]
15. The efficacy and safety of moclobemide compared to clomipramine in the treatment of panic disorder.
Krüger MB; Dahl AA
Eur Arch Psychiatry Clin Neurosci; 1999; 249 Suppl 1():S19-24. PubMed ID: 10361962
[TBL] [Abstract][Full Text] [Related]
16. Is there a role for selective monoamine oxidase inhibitor therapy in bulimia nervosa? A placebo-controlled trial of brofaromine.
Kennedy SH; Goldbloom DS; Ralevski E; Davis C; D'Souza JD; Lofchy J
J Clin Psychopharmacol; 1993 Dec; 13(6):415-22. PubMed ID: 8120155
[TBL] [Abstract][Full Text] [Related]
17. A double-blind placebo-controlled trial comparing fluvoxamine and imipramine in the treatment of panic disorder with or without agoraphobia.
Bakish D; Hooper CL; Filteau MJ; Charbonneau Y; Fraser G; West DL; Thibaudeau C; Raine D
Psychopharmacol Bull; 1996; 32(1):135-41. PubMed ID: 8927663
[TBL] [Abstract][Full Text] [Related]
18. Brofaromine (CGP 11 305 A) in treatment of depression: biological estimation of plasma concentrations.
Fritze J; Becker T; Ziegler V; Laux G; Riederer P
Pharmacopsychiatry; 1990 May; 23(3):131-4. PubMed ID: 2374771
[TBL] [Abstract][Full Text] [Related]
19. Clinical, biochemical and psychometric findings with the new MAO-A-inhibitors moclobemide and brofaromine in patients with major depressive disorder.
Laux G; Classen W; Sofic E; Becker T; Riederer P; Lesch KP; Struck M; Beckmann H
J Neural Transm Suppl; 1990; 32():189-95. PubMed ID: 2089089
[TBL] [Abstract][Full Text] [Related]
20. A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder.
Pollack MH; Lepola U; Koponen H; Simon NM; Worthington JJ; Emilien G; Tzanis E; Salinas E; Whitaker T; Gao B
Depress Anxiety; 2007; 24(1):1-14. PubMed ID: 16894619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
